Adenine base editor–mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adenine base editor–mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation
Authors
Keywords
-
Journal
BLOOD
Volume 141, Issue 10, Pages 1169-1179
Publisher
American Society of Hematology
Online
2022-12-13
DOI
10.1182/blood.2022016629
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disrupting the adult-globin promoter alleviates promoter competition and reactivates foetal-globin gene expression
- (2022) Sarah Topfer et al. BLOOD
- Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial
- (2022) Elisa Magrin et al. NATURE MEDICINE
- ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected
- (2022) Julian Boutin et al. CRISPR Journal
- Fetal hemoglobin in β hemoglobinopathies: Is enough too much?
- (2022) Martin H Steinberg AMERICAN JOURNAL OF HEMATOLOGY
- A precise and efficient adenine base editor
- (2022) Tianxiang Tu et al. MOLECULAR THERAPY
- Engineering a precise adenine base editor with minimal bystander editing
- (2022) Liang Chen et al. Nature Chemical Biology
- Development of LT-HSC-Reconstituted Non-Irradiated NBSGW Mice for the Study of Human Hematopoiesis In Vivo
- (2021) George Adigbli et al. Frontiers in Immunology
- Betibeglogene Autotemcel Gene Therapy for Non–β0/β0 Genotype β-Thalassemia
- (2021) Franco Locatelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype
- (2020) Leslie Weber et al. Science Advances
- Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity
- (2020) Michelle F. Richter et al. NATURE BIOTECHNOLOGY
- Therapeutic base editing of human hematopoietic stem cells
- (2020) Jing Zeng et al. NATURE MEDICINE
- Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
- (2020) Russell T. Walton et al. SCIENCE
- CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells
- (2020) Ibrahim C. Kurt et al. NATURE BIOTECHNOLOGY
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
- (2020) Haydar Frangoul et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia
- (2019) Sarah Marktel et al. NATURE MEDICINE
- CRISPResso2 provides accurate and rapid genome editing sequence analysis
- (2019) Kendell Clement et al. NATURE BIOTECHNOLOGY
- Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia
- (2019) Shuqian Xu et al. BLOOD
- Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells
- (2019) Petros Patsali et al. HAEMATOLOGICA
- Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease
- (2019) So Hyun Park et al. NUCLEIC ACIDS RESEARCH
- Adenine base editors catalyze cytosine conversions in human cells
- (2019) Heon Seok Kim et al. NATURE BIOTECHNOLOGY
- Search-and-replace genome editing without double-strand breaks or donor DNA
- (2019) Andrew V. Anzalone et al. NATURE
- Short-hairpin RNA against aberrant HBB[IVSI-110(G>A)] mRNA restores β-globin levels in a novel cell model and acts as mono- and combination therapy for β-thalassemia in primary hematopoietic stem cells
- (2018) Petros Patsali et al. HAEMATOLOGICA
- CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
- (2018) Emma Haapaniemi et al. NATURE MEDICINE
- Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
- (2018) Alexis A. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Short-hairpin RNA against aberrant HBB[IVSI-110(G>A)] mRNA restores β-globin levels in a novel cell model and acts as mono- and combination therapy for β-thalassemia in primary hematopoietic stem cells
- (2018) Petros Patsali et al. HAEMATOLOGICA
- Base editing: precision chemistry on the genome and transcriptome of living cells
- (2018) Holly A. Rees et al. NATURE REVIEWS GENETICS
- Gene Therapy for β-Hemoglobinopathies
- (2017) Marina Cavazzana et al. MOLECULAR THERAPY
- Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 Mice
- (2016) Susann Rahmig et al. Stem Cell Reports
- Easy quantitative assessment of genome editing by sequence trace decomposition
- (2014) Eva K. Brinkman et al. NUCLEIC ACIDS RESEARCH
- COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites
- (2014) Thomas J Cradick et al. Molecular Therapy-Nucleic Acids
- Non-transfusion-dependent thalassemias
- (2013) K. M. Musallam et al. HAEMATOLOGICA
- High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
- (2013) Yanfang Fu et al. NATURE BIOTECHNOLOGY
- The Molecular Basis of -Thalassemia
- (2013) S. L. Thein Cold Spring Harbor Perspectives in Medicine
- β THALASSAEMIA MUTATIONS IN MEDITERRANEAN POPULATIONS
- (2010) Antonio Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Global epidemiology of haemoglobin disorders and derived service indicators
- (2008) Bernadette Modell BULLETIN OF THE WORLD HEALTH ORGANIZATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started